Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A center for international blood and marrow transplant research (CIBMTR) analysis

Abhinav Deol, Salyka Sengsayadeth, Kwang Woo Ahn, Hai Lin Wang, Mahmoud Aljurf, Joseph Harry Antin, Minoo Battiwalla, Martin Bornhauser, Jean Yves Cahn, Bruce Camitta, Yi Bin Chen, Corey S. Cutler, Robert Peter Gale, Siddhartha Ganguly, Mehdi Hamadani, Yoshihiro Inamoto, Madan Jagasia, Rammurti Kamble, John Koreth, Hillard M. LazarusJane Liesveld, Mark R. Litzow, David I. Marks, Taiga Nishihori, Richard F. Olsson, Ran Reshef, Jacob M. Rowe, Ayman A. Saad, Mitchell Sabloff, Harry C. Schouten, Thomas C. Shea, Robert J. Soiffer, Geoffrey L. Uy, Edmond K. Waller, Peter H. Wiernik, Baldeep Wirk, Ann E. Woolfrey, Donald Bunjes, Steven Devine, Marcos de Lima, Brenda M. Sandmaier, Dan Weisdorf, Hanna Jean Khoury, Wael Saber

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes. RESULTS: In total, 158 patients (31%) had FLT3 mutations. Univariate and multivariate analyses revealed an increased risk of relapse at 3 years in the FLT3 mutated group compared with the wild-type (WT) group (38% [95% confidence interval (CI), 30%-45%] vs 28% [95% CI, 24%-33%]; P5.04; relative risk, 1.60 [95% CI, 1.15-2.22]; P5.0048). However, FLT3 mutation status was not significantly associated with nonrelapse mortality, leukemia-free survival, or overall survival. Although more patients in the FLT3 mutated group died from relapsed primary disease compared with those in the WT group (60% vs 46%), the 3-year overall survival rate was comparable for the 2 groups (mutated group: 49%; 95% CI, 40%-57%; WT group: 55%, 95% CI, 50%-60%; P5.20). CONCLUSIONS: The current data indicate that FLT3 mutation status did not adversely impact overall survival after HCT, and about 50% of patients with this mutation who underwent HCT were long-term survivors.

Original languageEnglish (US)
Pages (from-to)3005-3014
Number of pages10
JournalCancer
Volume122
Issue number19
DOIs
StatePublished - 2016

Keywords

  • 1 more
  • Acute myeloid leukemia
  • Allogeneic stem cell transplantation
  • FMS-like tyrosine kinase 3 (FLT3)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A center for international blood and marrow transplant research (CIBMTR) analysis'. Together they form a unique fingerprint.

Cite this